Clinical Update

Gabapentin: Highlights and Challenges

Gabapentin (Neurontin, Gralise, Horizant) was first approved by the US Food and Drug Administration (FDA) in 1993 for the treatment of epilepsy, and in 2004 was approved for the treatment of post-herpetic neurological pain.1 However, almost 95% of gabapentin prescriptions are for off-label use, including for some forms of anxiety disorders, management of pain-related conditions, alcohol use disorder (AUD), and others.2-19 Gabapentin is structurally related to the neurotransmitter gamma-aminobutyric acid (GABA), but has no effect on GABA binding, uptake, or degradation. Gabapentin has been shown to bind with high-affinity to voltage-activated calcium channels; however, the relationship of this binding to the therapeutic effects of gabapentin is unknown.20 Although gabapentin is generally considered safe at low doses, when used with other central nervous system (CNS) depressants such as opioids, antidepressants, antihistamines, and benzodiazepines, there is risk for respiratory depression, potentially resulting in death.16,20 In 2022, the U.S. Food and Drug Administration (FDA) administered a warning that patients using gabapentin who have respiratory risk factors may have serious breathing difficulties when used with opioids or other CNS depressants.22

Although gabapentin is not considered a controlled substance by the federal government, it does have a potential for misuse or abuse. As of September 2022, gabapentin was classified as a controlled substance in Alabama, Kentucky, Michigan, North Dakota, Tennessee, Virginia, and West Virginia.23 Gabapentin does not exhibit affinity for benzodiazepine, opiate (mu, delta, or kappa), or cannabinoid 1 receptors,1 but varying desired effects have been reported with higher doses, including improved sociability, increased energy, marijuana-like relaxation, or dissociation. 2,25,26 Gabapentin is primarily misused for recreational purposes, self-medication, or intentional self-harm.24 There was an increase in the annual gabapentin diversion reports to the US Researched Abuse, Diversion, and Addiction Related Surveillance System from 2002 to 2015,26 likely due to the availability of gabapentin from increased prescribing. Between 2009 and 2016, the prescription rate nearly doubled.27 By 2019, gabapentin had become the seventh most prescribed drug in the US28 and it still remains in the top 10 today.29 According to the State Unintentional Drug Overdose Reporting System from 23 states and the District of Columbia, overdose deaths in which gabapentin was detected doubled from 449 in the first quarter of 2019 to 959 in the second quarter of 2020.34 Whether this trend is stopped by increasing regulatory control or by focusing more on patient education is yet to be determined.30,31 Either way, people who use gabapentin with CNS depressants like opioids, illicit opioids, antidepressants, antihistamines, and benzodiazepines should be educated about the increased risk for respiratory depression and death. Signs and symptoms of gabapentin misuse or abuse can include the development of tolerance, self-dose escalation, and drug-seeking behavior.1,28,33,34 Because trends in gabapentin misuse and diversion are especially seen in those with a history of opioid abuse,2,4,20,34 understanding risk factors of the patient before prescribing can reduce the rate of gabapentin abuse.5,34

To better understand the frequency of the use of gabapentin when it has not been prescribed and the use of gabapentin with other substances, an analysis comparing Aegis gabapentin results in Q1 of both 2023 and 2024 was performed.

  1. Included in the data were the number of samples with positive gabapentin findings that did not indicate gabapentin as prescribed. However, it is possible that gabapentin may not be indicated as prescribed with regularity when it is a prescription medication. Samples in which there were no medications at all indicated as prescribed were excluded in an attempt to eliminate potential bias. Overall positivity of gabapentin in samples in which it was not indicated as prescribed was similar in both time periods, right at 1 in 10 samples.
  2. The overall positivity for gabapentin in both time periods, for all samples, regardless of whether or not it was indicated as prescribed, was nearly 25%, which is the highest positivity of any drug tested at Aegis currently.
  3. The top five drug classes that were co-positive with gabapentin were similar for Q1 of 2023 and 2024 and are discussed below.

Number 1: Opioids

The opioid class was co-positive with gabapentin more often than any other drug or drug class. The co-administration of opioids with gabapentin may cause an increase in both the gabapentin and opioid concentrations resulting in CNS depression, with symptoms including somnolence, sedation, and respiratory depression.1,2,20-22 Gabapentin has no direct ligand activity at opioid receptors, but it does potentiate the analgesic effect of most opioids.2 The combination of opioids and gabapentin has been shown to increase the risk of respiratory depression and has been associated with increased opioid-related death compared to opioid use without gabapentin.21 And because the “high” can be accentuated with concurrent use of these two drugs, requests for high-dose gabapentin from patients may be a signal for potential opioid misuse.4 It has been shown that gabapentin is a highly abused drug worldwide and those who prescribe gabapentin should be aware of its abuse potential,33 particularly in persons with a history of opioid misuse.2,4,20,34 On the other hand, there are many studies that show the benefits of using gabapentin in a multimodal approach to pain management and in pre- and post-op for varying surgeries, but this use is in the absence of opioids.6,7

Number 2: Buprenorphine + Opiate Antagonists

Buprenorphine and opioid antagonists tied as the second most prevalent drugs co-positive with gabapentin. This is not surprising as buprenorphine and naloxone (Suboxone) are often prescribed in the behavioral health community and are regularly co-positive. Because the co-administration of buprenorphine with gabapentin may result in CNS depression, with symptoms including somnolence, sedation, respiratory depression, it is recommended to use an alternative drug to gabapentin or to decrease the dose of one or both drugs. The use of opioid antagonists with gabapentin does not cause any known side effects.32 Literature is scant for the use of gabapentin in a substance use disorder (SUD) environment. One study found positive results for opioid use withdrawal using scheduled tizanidine, hydroxyzine, and gabapentin, instead of opioids or benzodiazepines, followed by an injectable extended-release naltrexone treatment.8

Number 3 and 4: Benzodiazepines and Antidepressants

Benzodiazepines were the third most co-positive drug class found with gabapentin and antidepressants were the fourth. Because some of the disease states overlap for these drugs, both will be discussed together.  The use of benzodiazepines with gabapentin may cause respiratory depression, or exacerbate the benzodiazepine side effects, such as dizziness, drowsiness, confusion, and difficulty concentrating. Anti-depressants are commonly prescribed alongside gabapentin for depression and anxiety, although when co-ingested there is an increased risk of hyponatremia and/or seizure.32 Gabapentin appears to be effective in some forms of anxiety disorders such as pre-operative anxiety, anxiety in breast cancer survivors, social phobia, social anxiety disorder, and severe panic disorder. No significant benefit of gabapentin has been conclusively observed in the treatment of obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), depression, major depressive disorder (MDD), posttraumatic stress disorder (PTSD), or stimulant use disorder.9-12

Number 5: Amphetamines and Alcohol Biomarkers

Amphetamines and alcohol biomarkers tied for the fifth most detected drug class with gabapentin present. There is little literature available concerning amphetamine with gabapentin, except that gabapentin has not been shown to be effective in treating methamphetamine dependence or stimulant use disorder.9 Also, the use of amphetamine with gabapentin may exacerbate seizures in those who have seizure disorders.32

Gabapentin is not FDA-approved for treating Alcohol Use Disorder (AUD) but has been shown to be safe and efficacious in treating alcohol withdrawal syndromes,11,13,14 for treating AUD by reducing cravings, improving the rate of abstinence, delaying the return to heavy drinking, and reducing alcohol consumption.9,15 Although it is unlikely that one single medication will be effective for all individuals with an AUD, much literature documents that gabapentin is best used in the withdrawal stages.11,13,14here is still more research needed to develop new, more effective, and diverse pharmacological treatment options for AUD.16

Gabapentin can be efficacious when co-prescribed in the management of pain or pain-related conditions, AUD, and some forms of anxiety disorders, but gabapentin can be dangerous when used with CNS depressants or in high doses alone.30,31 Prescribers may be able to minimize the increasing misuse of gabapentin and improve patient safety by vigilant monitoring and perhaps lowering doses for persons who may be at risk of gabapentin abuse, especially those who have a history of opioid abuse.2,4,20,34 Additionally, decreases in prescribing of gabapentin would likely decrease the amount of gabapentin available in the general population and possibly minimize diversion.27-29 The medical community overall especially must continue to educate patients about the risks of both ingesting large amounts of gabapentin and of administration of gabapentin with CNS depressants.1,28,33,34 





  1. Gabapentin [package insert]. NY, NY: Pfizer; 2017.
  2. Riley SB, Garbutt K, Crow C, Isbell TS, Scalzo AJ. Gabapentin prevalence: clinical and forensic experience in St. Louis, Missouri, USA. Forensic Sci Res. 2021;6(3):218-223. Published 2021 Nov 19. doi:10.1080/20961790.2021.1991075
  3. Mazurek, JM, Blackley DJ, Weissman DN. (2022). Trends in Gabapentin Detection and Involvement in Drug Overdose Deaths – 23 States and the District of Columbia (Morbidity and Mortality Weekly Report, Vol. 71, No. 19). S. Department of Health & Human Services, Centers for Disease Control and Prevention.
  1. Tomko JR, Prasad KM, Kubas S, Simpson T. The Association of Gabapentin Use and Dose With Substance Use Disorders Prior to Inpatient Mental Health Treatment: A Cross-Sectional Study. Prim Care Companion CNS Disord. 2018;20(4):18m02291. Published 2018 Aug 2. doi:10.4088/PCC.18m02291
  2. Kiliç Z, Aydin Özaslan E. Abuse and addiction in gabapentinoid drug users for neuropathic pain. Eur Rev Med Pharmacol Sci. 2023;27(12):5378-5389. doi:10.26355/eurrev_202306_32772
  3. Kong VK, Irwin MG. Gabapentin: a multimodal perioperative drug?. Br J Anaesth. 2007;99(6):775-786. doi:10.1093/bja/aem316
  4. Rech MA, Griggs C, Lovett S, Motov S. Acute pain management in the Emergency Department: Use of multimodal and non-opioid analgesic treatment strategies. Am J Emerg Med. 2022;58:57-65. doi:10.1016/j.ajem.2022.05.022
  5. Rudolf G, Walsh J, Plawman A, et al. A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment. Am J Drug Alcohol Abuse. 2018;44(3):302-309. doi:10.1080/00952990.2017.1334209
  6. Ahmed S, Bachu R, Kotapati P, et al. Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review. Front Psychiatry. 2019;10:228. Published 2019 May 7. doi:10.3389/fpsyt.2019.00228
  7. Martin JC, Gainer D. Psychiatric Uses of Gabapentin. Innov Clin Neurosci. 2022;19(7-9):55-60.
  8. Berlin RK, Butler PM, Perloff MD. Gabapentin Therapy in Psychiatric Disorders: A Systematic Review. Prim Care Companion CNS Disord. 2015;17(5):10.4088/PCC.15r01821. Published 2015 Oct 22. doi:10.4088/PCC.15r01821
  9. Freeman MP, Freeman SA, McElroy SL. The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues. J Affect Disord. 2002;68(1):1-23. doi:10.1016/s0165-0327(00)00299-8
  10. Kranzler HR. Overview of Alcohol Use Disorder. Am J Psychiatry. 2023;180(8):565-572. doi:10.1176/appi.ajp.20230488
  11. Anton RF, Latham P, Voronin K, et al. Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial. JAMA Intern Med. 2020;180(5):728-736. doi:10.1001/jamainternmed.2020.0249
  12. Wiercigroch D, Sheikh H, Hulme J. A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use. Subst Abuse Treat Prev Policy. 2020;15(1):4. Published 2020 Jan 13. doi:10.1186/s13011-019-0250-1
  13. Burnette EM, Nieto SJ, Grodin EN, et al. Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder. Drugs. 2022;82(3):251-274. doi:10.1007/s40265-021-01670-3
  14. Heinzerling KG, Shoptaw S, Peck JA, et al. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006;85(3):177-184. doi:10.1016/j.drugalcdep.2006.03.019
  15. Wolf C, Curry A, Nacht J, Simpson SA. Management of Alcohol Withdrawal in the Emergency Department: Current Perspectives. Open Access Emerg Med. 2020;12:53-65. Published 2020 Mar 19. doi:10.2147/OAEM.S235288
  16. Prisciandaro JJ, Hoffman M, Brown TR, et al. Effects of Gabapentin on Dorsal Anterior Cingulate Cortex GABA and Glutamate Levels and Their Associations With Abstinence in Alcohol Use Disorder: A Randomized Clinical Trial. Am J Psychiatry. 2021;178(9):829-837. doi:10.1176/appi.ajp.2021.20121757
  17. Toce MS, Chai PR, Burns MM, Boyer EW. Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity. J Med Toxicol. 2018;14(4):306-322. doi:10.1007/s13181-018-0685-1
  18. FDA (2019, Dec 19). “FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR); when used with CNS depressants or in patients with lung problems.”
  19. Lanham SW, Riley BR. Gapapentin Presents High Potential for Misuse. Pharmacy Times: Pharmacy Practice in Focus: Health Systems 2022;11(6). Published 2022 Nov 24.
  20. Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016;111(7):1160-1174. doi:10.1111/add.13324
  21. Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update. Drugs. 2021;81(1):125-156. doi:10.1007/s40265-020-01432-7
  22. Buttram ME, Kurtz SP, Dart RC, Margolin ZR. Law enforcement-deriveddata on gabapentin diversion and misuse, 2002–2015:diversion rates and qualitative research findings. PharmacoepidemiolDrug Saf. 2017;26(9):1083–6.
  23. Pauly NJ, Delcher C, Slavova S, Lindahl E, Talbert J, Freeman PR. Trends in Gabapentin Prescribing in a Commercially Insured U.S. Adult Population, 2009-2016. J Manag Care Spec Pharm. 2020;26(3):246-252. doi:10.18553/jmcp.2020.26.3.246
  24. Cannon Lucas. Gabapentin’s Impact on Drug-related Overdose Deaths.Community-University Health Care Center. Curbside Consult. 2022;20. Curbside Consult Volume 20 – Fall Edition 2022
  25. Lewis S. The Top 50 Drugs Prescribed in the United States. Healthgrades: Healthy Living Newsletter. [Updated: 29 September 2022, Cited: 2 May 2024].
  26. Covvey JR, Blakely ML, Singh R, Peckham AM, Evoy KE. Pharmacist, prescriber, and drug policy expert opinions on gabapentinoid misuse. Res Social Adm Pharm. 2023;19(4):599-609. doi:10.1016/j.sapharm.2022.12.001
  27. Anderson PA, McLachlan AJ, Abdel Shaheed C, Gnjidic D, Ivers R, Mathieson S. Deprescribing interventions for gabapentinoids in adults: A scoping review. Br J Clin Pharmacol. 2023;89(9):2677-2690. doi:10.1111/bcp.15798
  28. com [Internet]. c1996-2018 [Updated: 1 April 2024, Cited: 2 May 2024]. Available from:
  29. İspir GZ, Danışman M, Katar KS. A Hidden Pandemic? Abuse of Gabapentinoids: A Brief Review of Recent Studies. Curr Drug Res Rev. Published online November 28, 2023. doi:10.2174/0125899775268780231002064605
  30. Kuehn BM. Gabapentin Increasingly Implicated in Overdose Deaths. 2022;327(24):2387. doi:10.1001/jama.2022.10100